PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32987493-1	2020	BACKGROUND: Anlotinib is a newly developed small molecule multiple receptor tyrosine kinase (RTK) inhibitor that was approved for the treatment of patients with lung cancer in China.	anlotinib	12-21	ret proto-oncogene	Homo sapiens	67-91	
32987493-1	2020	BACKGROUND: Anlotinib is a newly developed small molecule multiple receptor tyrosine kinase (RTK) inhibitor that was approved for the treatment of patients with lung cancer in China.	anlotinib	12-21	ret proto-oncogene	Homo sapiens	93-96